«
»

Hemispherx drug for chronic fatigue held up by additional FDA demands

A decision on Hemispherx BioPharma’s new drug application for Ampligen, twice delayed by the FDA earlier this year, is still in limbo.
William A. Carter, CEO of the Center City biotech company, said last week the company is responding to issues raised by the Food and Drug Administration during its review of Ampligen, an experimental treatment for chronic fatigue syndrome.

A decision on Hemispherx BioPharma’s new drug application for Ampligen, twice delayed by the FDA earlier this year, is still in limbo.

William A. Carter, CEO of the Center City biotech company, said last week the company is responding to issues raised by the Food and Drug Administration during its review of Ampligen, an experimental treatment for chronic fatigue syndrome.

http://philadelphia.bizjournals.com/

The administrators of the ‘Living With ME’ website do not advocate the use of any particular type of medication, treatment or healthcare! YOU should ALWAYS seek advice from a DOCTOR / GP / CONSULTANT before undertaking or ceasing any treatment!

This entry was posted on Thursday, November 19th, 2009 at 10:00 am and is filed under ME News & Views. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.